<DOC>
	<DOC>NCT00193206</DOC>
	<brief_summary>In this trial we will evaluate ABI-007 with gemcitabine and epirubicin, utilizing the biweekly pegfilgrastim support, in order to further improve upon the effectiveness and favorable toxicity of this triplet.</brief_summary>
	<brief_title>Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer</brief_title>
	<detailed_description>Upon determination of eligibility, patients will be receive both induction neo-adjuvant regimen and a postoperative adjuvant regimen: Induction Neo-adjuvant: Epirubicin + Gemcitabine + ABI-007 + Pegfilgrastim Postoperative Adjuvant: Gemcitabine + ABI-007 + Pegfilgrastim Upon completion of chemotherapy, all ER and/or PR+ patients will receive Tamoxifen or an aromatase inhibitor at physician discretion.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>To be included in this study, you must meet the following criteria: Locally advanced/inflammatory adenocarcinoma of the breast 18 years of age or older Normal heart function Able to perform activities of daily living with minimal assistance No prior chemotherapy for breast cancer Adequate bone marrow, liver and kidney function No evidence or history of significant cardiovascular abnormalities Sentinel node or axillary dissection Sign an informed consent form You cannot participate in this study if any of the following apply to you: Pregnant or breast feeding History of heart disease with congestive heart failure Heart attack within the previous 6 months Prior chemotherapy or hormone therapy for breast cancer History of active uncontrolled infection Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Locally Advanced Breast Cancer</keyword>
	<keyword>Inflammatory Breast Cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Abraxane</keyword>
	<keyword>nab Paclitaxel</keyword>
	<keyword>Epirubicin</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemzar</keyword>
</DOC>